Does not preclude administration of appropriate fluid & electrolyte replacement therapy. Should not be used for prolonged periods until underlying cause of diarrhoea has been investigated. In acute diarrhoea, discontinue administration if clinical improvement is not observed w/in 48 hr. Stop therapy at the earliest signs of abdominal distension in AIDS patients. Reports of obstipation w/ an increased risk for toxic megacolon in AIDS patients w/ infectious colitis from both viral & bacterial pathogens. Discontinue administration if clinical improvement is not observed w/in 48 hr in patients taking this medicine to control episodes of diarrhoea associated w/ IBS. Only take this medicine to treat acute episodes of diarrhoea associated w/ IBS if IBS was previously diagnosed. Patient ≥40 yr & it has been some time since last IBS attack or symptoms are different this time; patient recently passed blood from bowel; suffers from severe constipation; feeling sick or vomiting; lost appetite or wt; has difficulty or pain passing urine; w/ fever; recently travelled abroad. Reports of cardiac events including QT prolongation & torsades de pointes in association w/ overdose; do not exceed recommended dose &/or duration of treatment. Should not be taken by patients w/ rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. May impair ability to drive or operate machinery. Patients w/ hepatic impairment. Not advisable to administer in pregnancy, especially during the 1st trimester. Not recommended during breast-feeding.
Sign Out
